Figure 2. Scheme of ctDNA biomarker level during medulloblastoma development, therapy, and progression. Sequential analysis of CSF supports diagnosis and early detection of minimal residual disease (MRD) as well as clinical decisions for the best benefit of the patient. CSF: Cerebrospinal fluid.
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.
By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data.
